Cytoplasmic tail of IL-13Ralpha2 regulates IL-4 signal transduction by Andrews, Allison-Lynn et al.
Biochemical Basis of Respiratory Disease 873
Cytoplasmic tail of IL-13Rα2 regulates IL-4
signal transduction
Allison-Lynn Andrews*1, Ida Karin Nordgren†, Isabelle Kirby†, John W. Holloway*, Stephen T. Holgate*,
Donna E. Davies* and Ali Tavassoli†
*School of Medicine, University of Southampton, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, U.K., and †School of Chemistry,
Highﬁeld Campus, University of Southampton, University Road, Southampton SO17 1BJ, U.K.
Abstract
IL (interleukin)-4 and IL-13 are key cytokines in the pathogenesis of allergic inﬂammatory disease. IL-4
and IL-13 share many functional properties as a result of their utilization of a common receptor complex
comprising IL-13Rα1 (IL-13 receptor α-chain 1) and IL-4Rα. The second IL-13R (IL-13 receptor) has been
identiﬁed, namely IL-13Rα2. This has been thought to be a decoy receptor due to its short cytoplasmic tail
and its high binding afﬁnity for IL-13 but not IL-4. IL-13Rα2 exists on the cell membrane, intracellularly and
in a soluble form. Recent reports revealed that membrane IL-13Rα2 may have some signalling capabilities,
and a soluble form of IL-13Rα2 can be generated in the presence of environmental allergens such as DerP.
Interestingly, IL-13Rα2 has also been shown to regulate both IL-13 and IL-4 response in primary airway cells,
despite the fact that IL-13Rα2 does not bind IL-4. The regulator mechanism is still unclear but the physical
association of IL-13Rα2w i t hI L - 4 R α appears to be a key regulatory step. These results suggest that the
cytoplasmic tail of IL-13Rα2 may interfere with the association or activation of signalling molecules, such
as JAK1 (Janus kinase 1), on IL-4Rα and thus prevents downstream signal cascade. The receptor has more
complicated functions than a simple decoy receptor. In this review, we discuss newly revealed functions of
IL-13Rα2.
Introduction
IL (interleukin)-4 and IL-13 are pleiotropic cytokines with
key roles in the pathogenesis of asthma and other atopic
diseases. They induce VCAM-1 (vascular cell adhesion
molecule-1) on vascular endothelium and thus direct the
migration of T-lymphocytes, monocytes, basophils and eo-
sinophils to the inflammation site [1–3]. In asthma, IL-4 and
IL-13 contribute to inflammation and to airway obstruction
through the induction of mucin gene expression and
the hypersecretion of mucus [4]. Both cytokines inhibit
eosinophil apoptosis and promote eosinophilic inflammation
by inducing chemotaxis and activation through the increased
expression of eotaxin [5].
IL-13 mediates its functions via its cognate receptor, a
heterodimercomposedoftheIL-4Rα (IL-4receptorα-chain)
and the IL-13-binding protein, IL-13Rα1 [IL-13R (IL-13
receptor) α-chain 1] [6]. The IL-13Rα1–IL-4Rα complex can
act as an alternative receptor for IL-4, especially in cells that
lack the common γ-chain (γc) that usually forms a complex
with IL-4Rα to bind IL-4 [7]. The IL-13R complex is formed
in a sequential manner: IL-13 first binds to IL-13Rα1b e f o r e
recruiting IL-4Rα to form a high-affinity, signalling complex
[8]. In the case of IL-4 binding to IL-13Rα1–IL-4Rα,
Key words: asthma, cytokine receptor, interleukin 4 (IL-4), interleukin 13 (IL-13), interleukin 13
receptor α-chain 1 (IL-13Rα1), signal transduction.
Abbreviations used: IFNγ,i n t e r f e r o nγ; IL, interleukin; IL-13R (etc.), IL-13 receptor (etc.); IL-
13Rα,I L - 1 3α-chain; JAK, Janus kinase; MMP, matrix metalloproteinase; STAT, signal transducer
and activator of transcription; TGFβ, transforming growth factor-β.
1To whom correspondence should be addressed (email ala@soton.ac.uk).
IL-13Rα1 contributes little to the overall binding affinity
and its role within this complex remains unknown [9].
IL-13Rα2
A second IL-13 binding protein, IL-13Rα2, has been
identified [10]. It shares 37% homology with IL-13Rα1a n d
binds IL-13 with high affinity, but not IL-4 [8]. Binding
studies have shown that IL-13Rα2 has the characteristics
of a negative regulator, with a fast association rate but
an exceptionally slow dissociation rate [8]. IL-13Rα2h a s
a short cytoplasmic tail that lacks any obvious signalling
motif and is unable to instigate a signal through the STAT
(signal transducer and activator of transcription) 6 pathway.
IL-13Rα2 appears to regulate IL-13, as receptor expression
makes cells unresponsive to IL-13 despite the high binding
affinity.Thishighaffinity,togetherwiththefindingofsoluble
IL-13Rα2 in vivo [11], has led to speculation that IL-13Rα2
is a decoy receptor. However, it has been revealed that
membrane IL-13Rα2 may have some signalling capabilities.
Fichtner-Feigl et al. [12] have suggested that IL-13 can
signal through IL-13Rα2 in macrophages to activate an AP-1
(activator protein 1) variant containing c-Jun and Fra-2,
leadingtoIL-13-inducedTGFβ (transforminggrowthfactor-
β)-mediated fibrosis [12]. They found that prevention of
IL-13Rα2 expression reduced the production of TGFβ1i n
oxazolone-induced colitis and that prevention of IL-13Rα2
expression, IL-13Rα2 gene silencing or blockade of IL-
13Rα2 signalling led to marked down-regulation of TGFβ1
production and collagen deposition in bleomycin-induced
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lungfibrosis.ThisgroupalsoshowedthatIL-13signallingvia
the IL-13Rα2 is a key initiation point for a complex fibrotic
programme in the colon consisting of TGFβ1 activation,
IGF-1 (insulin-like growth factor 1) and EGR-1 (early
growth-response gene product 1) expression, myofibroblast
apoptosis, and myofibroblast production of collagen [13].
Expression of IL-13Rα2 varies across cell types and can be
induced by inflammation and cytokines [14,15]. A role for
IL-13Rα2 as a potent modulator of inflammatory responses
in asthma is suggested by the IL-13- and IL-4-dependent
up-regulation of IL-13Rα2 in primary bronchial epithelial
cells and the demonstration that overexpression of IL-13Rα2
in primary airway cells decreases IL-13-dependent STAT6
phosphorylation and eotaxin production [16]. Daines et al.
[17] demonstrated that IL-13Rα2 is largely an intracellular
molecule,whichisrapidlymobilizedfromintracellularstores
after treatment with IFNγ (interferon γ) [17]. Up-regulation
of IL-13Rα2 surface expression in response to IFNγ was
rapid, did not require protein synthesis, and resulted in
diminished IL-13 signalling. Furthermore, there appeared
to be communication between the intracellular pools and
the cell surface as prolonged treatment of cells with trypsin
revealed an ongoing decrease in total cell IL-13Rα2 [18].
The authors suggest that this continued decline in IL-13Rα2
was due to mobilization of the cytoplasmic IL-13Rα2t ot h e
surfacewhereitwassusceptibletotrypsin-mediatedcleavage.
Soluble IL-13Rα2 has been postulated as a critical
endogenous modulator of IL-13 responses. Specific blockade
of IL-13 by soluble IL-13Rα2 to allergen challenged mice
reversed airway hyperreactivity and mucus production
[19], but the mechanism for the generation of soluble
IL-13Rα2 remains unclear. Soluble cytokine receptors can be
generated by several mechanisms, including the proteolytic
cleavage of membrane-bound receptor proteins from the
cell surface and alternative splicing of mRNA transcripts.
Matsumura et al. [20] reported that endogenous MMP(s)
[matrix metalloproteinase(s)] solubilize IL-13Rα2 in airway
epithelial cells, whereas Chen et al. [21] demonstrated that
soluble IL-13Rα2 can be produced by means of direct
cleavage by MMP-8 and that MMP-8 contributes to the
solubilization of IL-13Rα2 in BALF (bronchoalveolar lavage
fluid) in house dust mite-treated mice. Furthermore, this
group showed that exposure to mould or house dust mite
allergens resulted in degradation of surface IL-13Rα2 [22].
This reduction in receptor levels may contribute to the
pathogenesis of allergic disorders in individuals with allergy
becauseofthelossofIL-13Rα2inhibitionofIL-13responses.
They also found that an alternatively spliced transcript of
the mouse IL-13Rα2 gene generates biologically relevant
soluble IL-13Rα2p r o t e i nin vitro, which can effectively
block IL-13-dependent STAT6 activation [23]. Thus these
results indicate that the generation of soluble IL-13Rα2 can
occur from an alternative transcript encoding a soluble form
in addition to the cleavage of membrane-bound IL-13Rα2.
We have observed that expression of IL-13Rα2 in primary
human fibroblast cells varied considerably between volun-
teers [24]. There is a correlation between IL-13Rα2 baseline
levels and eotaxin release, suggesting that IL-13Rα2i sa b l e
to regulate IL-13-mediated effects in fibroblasts. IL-13-
mediated eotaxin release from fibroblasts with low levels of
IL-13Rα2 was significantly higher than that from fibroblasts
with high receptor expression. Fibroblasts with high surface
levels of IL-13Rα2 were virtually unresponsive to IL-13 as
the amount of eotaxin released from these cells was not
significantly different from the untreated control [25]. The
natural variability in IL-13Rα2 expression remains unclear as
therearenoknownpolymorphismsinthepromoterregionof
theIL-13Rα2gene.Receptorexpressionwasnotlinkedtothe
ageorsexofvolunteersandtherewasonlyaslightassociation
with atopy. However, in light of recent reports, differences
in cumulative environmental allergen exposure or in the
intrinsic regulation of the production of soluble IL-13Rα2
could lead to decreased IL-13Rα2 in subjects and increased
susceptibility to IL-13. A variant of IL-13, R110Q, has been
associated with atopy and atopic diseases such as atopic
dermatitis and rhinitis [26,27]. We have also demonstrated
that IL-13Rα2 has a lower affinity for R110Q and thus is
unable to regulate this cytokine as effectively as wild-type
IL-13, thus leading to a more sustained response than that
observed for wild-type IL-13 [28]. If this is then linked
with a natural variation in IL-13Rα2, the ability of R110Q
to contribute to an allergic response is dependent not only
on its reduced affinity for IL-13Rα2, but also on naturally
occurring levels of IL-13Rα2. Thus IL-13Rα2 may represent
an important biomarker for asthma and allergic diseases.
Regulation of IL-13 and IL-4 signalling
The exact mechanism by which IL-13Rα2 regulates IL-13 is
still under investigation. It has been suggested that IL-13Rα2
present on the cell surface competes with the IL-4Rα/IL-
13Rα1 complex for IL-13. We have previously characterized
the binding of IL-13 to its receptor components and shown
that IL-13Rα2 binds IL-13 with a significantly higher
affinity than IL-13Rα1, a property that is derived primarily
from its extremely low dissociation rate [8]. Thus, once
IL-13 has been captured by IL-13Rα2, it is effectively
sequestered from the lower-affinity IL-13Rα1 signalling
receptor. Alternatively, a soluble form of the receptor might
be present in interstitial spaces, where it can sequester IL-13
to limit its bioavailability and suppress activation of receptor
complexes on the cell surface. The presence of a soluble
form represents a potential mechanism for IL-13Rα2t oh a v e
effects on cells distant from its production. Daines et al. [18]
reported that soluble IL-13Rα2 released from transfected
cells was unable to inhibit IL-13 signalling in untransfected
cells, probably because the level of soluble receptor was
low [18]. However, during inflammation the levels may
be higher and therefore functionally relevant. The in-
hibitory effects of the IL-13Rα2 on IL-13 appeared to be
rapid and persistent but could be overcome by increasing
concentrations of IL-13. Thus the ability of IL-13Rα2t o
quench IL-13 responses is dependent on both the level of
expression of the receptor and the amount of IL-13 present.
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IL-13Rα2isoverexpressedinavastmajorityofhigh-grade
astrocytomas, and it has been proposed as a tumour-speci-
fic antigen [29]. Studies of the expression of the membrane-
anchored form of IL-13Rα2 in tumour cells suggest that it
also functions as a negative regulator of IL-13 in these cells.
However, it has been shown that it not only competes with
IL-13Rα1 for binding of IL-13, but it also promotes IL-13
internalization,resultinginmarkedsuppressionofIL-13acti-
vity[30].Thispropertyhasbeenexploitedfortumourtarget-
ing by using an IL-13 Pseudomonas exotoxin fusion protein.
This is a highly specific cytotoxin to medulloblastoma cell
lines expressing IL-13Rα2 and has led to the proposal that
IL-13Rα2 might serve as a tumour-specific antigen for
active immunotherapy of brain tumours [31]. Similarly, lung
fibroblasts isolated from the most severe form of idiopathic
interstitial pneumonia (usual interstitial pneumonia) exhibit
increasedexpressionofIL-4andIL-13receptorsubunits,and
these can be targeted with an IL-13 Pseudomonas exotoxin
fusion protein [32]. Significantly, this effect was dependent
on expression not only of IL-13Rα2, but also of IL-4Rα.
The variability in the level of IL-13Rα2 on the surface
of primary epithelial cells is inversely correlated to their
responsiveness not only to IL-13 but also to IL-4, despite the
fact that IL-13Rα2 does not bind IL-4. Increased levels of
IL-13Rα2 on the cell surface lead to a significant inhibition
of both IL-13- and IL-4-mediated effects. The addition of
neutralizing antibodies to IL-13Rα2 prevented the inhibition
of the IL-13-stimulated responses and surprisingly IL-
4-mediated responses as well [25]. The involvement of
IL-13Rα2 in the regulation of IL-4 is supported by evidence
that IL-13Rα2 forms a complex with IL-4Rα when cells
are exposed to IL-4. The fact that IL-13Rα2 associates with
IL-13Rα1whencellsareexposedtoIL-13,butnotIL-4,rules
out the possibility that IL-13Rα2 inhibits IL-4 signalling by
sequestering IL-13Rα1 [33]. Similarly, IL-13Rα2 is unable to
bind IL-4, and therefore it would be unable to inhibit IL-4
signalling by sequestering the ligand.
The cytoplasmic tail of IL-13Rα2
regulates IL-4
A more likely explanation is that the short cytoplasmic tail of
IL-13Rα2 might interfere with the association or activation
of signalling molecules, which, in turn, prevents downstream
signal cascade. The intracellular domain of IL-4Rα contains a
membrane-proximal Box-1 sequence that serves as a docking
site for JAK (Janus kinase) 1. It may be this site at which
IL-13Rα2 is able to regulate IL-4 responses, as blocking the
interaction of this signalling molecule with its receptor com-
plex completely inhibits the JAK/STAT6 signalling pathway.
A similar mechanism has been linked to the abnormal pro-
liferation of glioblastoma cells, in which IL-4-mediated anti-
tumour activity in rodent experimental gliomas is abrogated
by aberrant expression of IL-13Rα2by the glioblastoma cells
[33]. This involves the cytoplasmic tail of IL-13Rα2, which
partly blocks IL-4-mediated activation of STAT6 and up-
regulates the activation of STAT3, although the latter does
not require a direct physical interaction between STAT3 and
IL-13Rα2 [34]. Furthermore, although glioblastoma cells fail
to express the alternative IL-4Rα/common γ-chain receptor
complex,thisformofIL-4Rispresentonbothepithelialcells
and fibroblasts, suggesting that IL-13Rα2 has the ability to
inhibit IL-4Rα in either signalling configuration.
Conclusion
The IL-4/IL-13 pathway is an extremely important mediator
of inflammatory responses. Small genetic differences such as
theexpressionoftheIL-13variant,R110Q,orenvironmental
exposure to allergens can lead to the dysregulation of IL-4
and IL-13 that contributes to an asthmatic phenotype. Thus
a complete understanding of how IL-13Rα2 regulates these
two important cytokines may lead to the development of
a novel therapy for asthma that selectively targets these
cytokines.PreviousattemptstoaugmenteitherIL-4orIL-13
have been relatively unsuccessful due to their shared receptor
system. By targeting IL-13Rα2, which has the ability to
regulate both molecules, the problem of subverting an
alternative pathway can be overcome. Such a multifunctional
interaction would identify the transmembrane form of IL-
13Rα2 as a powerful suppressor of Th2-mediated responses.
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